Vizsgálati helyszín
GasthuisZusters Antwerpen
Antwerp, 2000, BelgiumMég nincs intézményhez kötve
- 12futó vizsgálat
- 16lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 28 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis19 vizsgálat
- 2. fázis5 vizsgálat
- 4. fázis2 vizsgálat
- 1. fázis1 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Lezárult16 vizsgálat
- Fut, nem toboroz10 vizsgálat
- Toboroz2 vizsgálat
- Fő szponzor
- Abivax S.A.2 vizsgálat
- AstraZeneca2 vizsgálat
- Hoffmann-La Roche2 vizsgálat
- Pfizer2 vizsgálat
- UZ Leuven2 vizsgálat
- és még 18
Futó vizsgálatok
Toboroz
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy
NCT03899077· 2. fázis· Ziekenhuis Aan De Stroom· Forrás
Fut, nem toboroz
Treat-CMV
2022-500714-25-01· 3. fázis· UZ Leuven· Forrás
Toboroz
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
ABTECT - Maintenance
NCT05535946· 3. fázis· Abivax S.A.· Forrás
Fut, nem toboroz
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059· 3. fázis· Janssen Pharmaceutica N.V., Belgium· Forrás
Fut, nem toboroz
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
NCT03903835· 3. fázis· Karolinska Institutet· Forrás
Fut, nem toboroz
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516· 3. fázis· Aragon Pharmaceuticals, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Fut, nem toboroz
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738· 1. fázis· Enliven Therapeutics· Forrás
Lezárult
Multicenter randomized controlled clinical trial comparing ebastine and mebeverine as treatment of irritable bowel syndrome
2022-501780-41-00· 3. fázis· UZ Leuven· Forrás
Lezárult
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216· 3. fázis· Abivax S.A.· Forrás
Lezárult
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke
NCT05643573· 3. fázis· Bayer AG· Forrás
Lezárult
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
NCT05518123· 4. fázis· Pfizer· Forrás
Lezárult
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400· 4. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT05081609· 1/2. fázis· Ascendis Pharma Oncology Division A/S· Forrás
Lezárult
Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose
Combination versus Nivolumab Monotherapy after Complete Resection of
Stage III-IV Melanoma
NCT05002569· 3. fázis· Bristol Myers Squibb International Corporation· Forrás
Fut, nem toboroz
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378· 2. fázis· BioNTech SE· Forrás
Lezárult
Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART)
2024-511140-37-00· 2. fázis· Universitair Ziekenhuis Gent· Forrás
Lezárult
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
NCT04221945· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
NCT03661320· 3. fázis· Bristol-Myers Squibb· Forrás
Lezárult
CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors
NCT03511391· 2. fázis· University Hospital, Ghent· Forrás
Lezárult
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
NCT02947347· 3. fázis· Pharmacyclics LLC.· Forrás
Fut, nem toboroz
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681· 3. fázis· Acerta Pharma BV· Forrás
Hibát jelzek